Skip to content
ppharmaranks
Menu
Class IIOngoing

Amphotericin B Liposome for Injection recall

FDA recall D-0493-2024 · initiated Apr 19, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated May 15, 2024How we research

SUN PHARMACEUTICAL INDUSTRIES INC recalled Amphotericin B Liposome for Injection in Apr 2024 — an FDA Class II recall (D-0493-2024) because Out of specification for assay.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Out of specification for assay

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: BAE0055A, BAE0056A, BAE0068A, Exp. Date 03/2026

Quantity recalled: 11,016 vials

Details

Product
Amphotericin B Liposome for Injection, 50mg vials, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Medicare Limited, Baska Ujeti Road, Ujeti Halol-389350, Gujarat, India. NDC 62756-233-01
Recalling company
Sun Pharm Industries
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide within the United States
Initiated
Apr 19, 2024
FDA report date
May 15, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Amphotericin B Liposome for Injection recalled?
SUN PHARMACEUTICAL INDUSTRIES INC recalled Amphotericin B Liposome for Injection in Apr 2024 — an FDA Class II recall (D-0493-2024) because Out of specification for assay. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Amphotericin B Liposome for Injection recalled?
Per the FDA enforcement record, the reason for recall D-0493-2024 was: Out of specification for assay
Is a recalled Amphotericin B Liposome for Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Amphotericin B Liposome for Injection are affected?
Distributed: Nationwide within the United States. The recall covers these lots — Lot #: BAE0055A, BAE0056A, BAE0068A, Exp. Date 03/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0493-2024.

Source: openFDA Drug Enforcement record D-0493-2024

← All drug recalls